We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics - An LGC Company

Download Mobile App

LumiraDx Presents Its Innovative, Next Generation Point of Care Diagnostics Platform at MEDICA 2021

By LabMedica International staff writers
Posted on 16 Nov 2021
Print article
Image: LumiraDx at MEDICA 2021 (Photo courtesy of LumiraDx)
Image: LumiraDx at MEDICA 2021 (Photo courtesy of LumiraDx)

LumiraDx (London, UK) presented its innovative, next generation point of care diagnostics platform and seamless digital connectivity at this year’s MEDICA, the world’s largest medical trade fair, held from 15-18 November in Düsseldorf, Germany. For more than 40 years it has welcomed several thousand exhibitors from more than 50 countries. The exhibition covered all aspects of medicine and clinical care; from electromedical equipment and medical technology, physiotherapy and orthopedic technology to laboratory equipment and diagnostics.

At MEDICA 2021, LumiraDx presented the LumiraDx Platform, its innovative, disruptive solution designed to deliver lab-comparable performance to transform community care. The LumiraDx Platform is an innovative, next generation point of care diagnostic system that combines a small, portable instrument, advanced low cost test strip and seamless secure digital connectivity to the Cloud and hospital IT systems. The LumiraDx Platform and tests are designed on the same principles as lab analyzer systems, to deliver accurate results compared to laboratory reference assays across a number of parameters, in a portable, easy-to-use point of care solution. Easy and intuitive to use, it requires only basic training and is designed to be affordable and accessible at the point of care.

LumiraDx offers a broad menu of lab comparable results on the LumiraDx Platform that aims to transform community care. It has developed SARS-CoV-2 antigen and antibody tests that provide lab comparable results for COVID-19 testing in minutes on a single platform. The LumiraDx Platform menu also includes point of care tests for INR and D-Dimer with high levels of accuracy comparable to central lab-based tests. The company has a pipeline of more than 30 assays, initially focused on some of the most common conditions being diagnosed or managed with POC testing such as coagulation disorders, infectious diseases, cardiovascular and diabetes.

Related Links:

Gold Supplier
Immunofluorescence Analyzer
Getein 1160
Silver Supplier
Helicobacter Pylori Test
Microplate Washer
Molecular Diagnostic System
FlashDetect Flash48

Print article



view channel
Image: QIAGEN has acquired a majority stake in enzymes provider BLIRT S.A. (Photo courtesy of QIAGEN)

Qiagen Acquires Enzymes Provider Blirt to Strengthen Sample Technologies Business

QIAGEN N.V. (Venlo, Netherlands) has signed agreements to acquire a 96% majority ownership stake in BLIRT S.A. (Gdansk, Poland), a manufacturer of recombinant enzymes for the life science industry.... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.